Page 2 - Read Online
P. 2
Topic: Bone
Microenvironment and Bone
Metastasis
Metastasis is a highly complex albeit relatively inefficient
process, with bone the dominant site for involvement
across a range of solid tumours. The multiple interactions
within the bone microenvironment from the earliest phases
when establishment of the pre-metastatic niche occurs,
Prof. Robert through tumour cell homing, dormancy and subsequent
reactivation leading to overt metastasis are of great
Professor Robert (Rob) Coleman is the interest and our knowledge from ever more sophisticated
Yorkshire Cancer Research Professor preclinical models is unraveling the complex biological
of Medical Oncology and Honorary processes involved. For several decades there has been
Consultant in the Academic Unit of interest in the potential of bone-targeted agents, through
Clinical Oncology at Weston Park their profound effects on bone physiology, to modify
Hospital, Sheffield. He graduated in
medicine from Kings College Hospital the process of metastasis and have effects on important
Medical School in 1978 and trained in disease outcomes such as recurrence and survival. This
London and Edinburgh before moving to hypothesis has been the focus of extensive laboratory and
Sheffield in 1991. clinical research in a several tumour types with variable
For more than 20 years he has been results. This Special Issue aims to bring together the
instrumental in developing clinical cancer recent progress made from across laboratory and clinical
research in the city and surrounding settings and set out challenges for future research and
clinical network. During that time he has clinical trials to try and minimise the enormous clinical
held many leadership roles within the local
university, the NIHR Cancer Research burden associated with metastatic bone disease.
Network and the NCRI. Since 2014 he has
been a part-time Medical Director for the Areas for consideration include:
independent medical education provider, Bone metastases (pathophysiology, epidemiology,
prIME Oncology™ alongside his ongoing diagnostics, clinical features, prevention, treatment).
role within the university. Preclinical models of metastasis.
Since 2012, Rob is a member of the ESMO Bone microenvironment in cancer (stem cell, bone cell
Breast Cancer Faculty Group; he served and cancer interactions).
as National Representative for the UK Bone targeted therapy (pharmacology, therapeutic
between 2012 and 2015.
Rob is passionate about improving the care targets, drug development, clinical trials).
of cancer patients through research and has Bone imaging (clinical and animal, skeletal interventional
particular interests in new developments in radiology).
the management of breast cancer and the Bone biomarkers (clinical and translational applications).
effects of cancer and its various treatments
on the bones. He has written more than
350 scientific articles and book chapters
and leads a number of national and
international clinical trials.
